Biology of TNFα and IL-10, and their imbalance in heart failure

Heart Failure Reviews

Volumn 14, Issue 2, 2009, Pages 113-123

  Kaur, Kuljeet ^a   Dhingra, Sanjiv ^b   Slezak, Jan ^d   Sharma, Anita K ^b,c   Bajaj, Anju ^b,c   Singal, Pawan K ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Antioxidants; Heart failure; Inflammation; Oxidative stress

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOKINE; DEXAMETHASONE; ETANERCEPT; FAS ASSOCIATED DEATH DOMAIN PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; LOSARTAN; PENTOXIFYLLINE; PREDNISONE; PROTEIN KINASE C; RECOMBINANT INTERLEUKIN 10; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG BINDING SITE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RECEPTOR BINDING; EXTRACELLULAR MATRIX; HEART FAILURE; HEART PROTECTION; HUMAN; LOW DRUG DOSE; MOLECULAR BIOLOGY; MUSCLE ISCHEMIA; NONHUMAN; OXIDATIVE STRESS; TISSUE INJURY; UNSTABLE ANGINA PECTORIS; BIOSYNTHESIS; IMMUNOLOGY; METABOLISM; REVIEW;

HEART FAILURE; HUMANS; INTERLEUKIN-10; OXIDATIVE STRESS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 63449104627     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9104-z     Document Type: Article

References (143)

1. Kaur K, Sharma AK, Singal PK (2006) Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol 291:H106-H113. doi: 10.1152/ajpheart.01327.2005
2. Dhingra S, Sharma AK, Singla DK, Singal PK (2007) p38 and ERK 1/2 MAPkinases mediate interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis. Am J Physiol Heart Circ Physiol 293:H3524-H3531. doi: 10.1152/ajpheart.00919.2007
3. Kaur K, Sharma AK, Dhingra S, Singal PK (2006) Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol 41:1023-1030. doi: 10.1016/ j.yjmcc.2006.08.005
4. Pulkki KJ (1997) Cytokines and cardiomyocyte death. Ann Med 29:339-343. doi: 10.3109/07853899708999358
5. Yao YY, Yin H, Shen B, Chao L, Chao J (2007) Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction. J Card Fail 13:588-596. doi: 10.1016/j.cardfail.2007.04.009
6. Mann DL, Young JB (1994) Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest 105:897-904. doi: 10.1378/chest.105.3.897
7. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: The cytokine hypothesis. J Card Fail 2:243-249. doi: 10.1016/S1071-9164(96)80047-9
8. Langer SE, Scheer JF (1995) Solved-the riddle of illness. Keats Pub, USA
9. Deidier A (1725) Dissertation Medecinal et Chirurgical sur les Tumeurs, Paris
10. Kolmel K, Pfahlberg A, Mastrangelo G et al (1999) Infections and melanoma risk: Results of a multicentre EORTC case-study. Melanoma Res 9:511-519
11. Busch W (1868) Aus der Sitzung der medicinischen Section vom 13 November 1867. Berl Klin Wochenschr 5:137
12. Bruns P (1888) Die Heilwirkung des Erysipelas auf Geschwülste. Beitr Klin Chir 3:443
13. Lassar O (1891) Zur Erysipelimpfung. Dtsch Med Wochenschr 17:889
14. Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci 105:487-511. doi: 10.1097/00000441-189305000-00001
15. Shear HJ, Marks ES (1962) Measuring self-confining behaviour patterns. J Clin Psychol 18:26-28. doi:10.1002/ 1097-4679(196201)18:1<26::AID-JCLP2270180107>3.0.CO;2-S
16. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670. doi: 10.1073/pnas.72.9.3666
17. Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN (1985) Human tumor necrosis factor: Production, purification and characterization. J Biol Chem 260:2345-2354
18. Matthews N (1978) Tumour-necrosis factor from the rabbit. II. Production by monocytes. Br J Cancer 38:310-315
19. Fiers W (1991) Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 285:199-221. doi: 10.1016/ 0014-5793(91)80803-B
20. Spiegelman BM, Hotamisligil GS (1993) Through thick and thin: Wasting, obesity, and TNF alpha. Cell 73:625-627. doi: 10.1016/ 0092-8674(93)90243-J
21. Fiers W, Beyaert R, Brouckaert P et al (1987) Tumor necrosis factor: A potential antitumor agent? J Interferon Res 7:627-634
22. Loetscher H, Pan YC, Lahm HW et al (1990) Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61:351-359. doi: 10.1016/0092-8674(90)90815-V
23. Smith CA, Davis T, Anderson D et al (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019-1023. doi: 10.1126/science.2160731
24. Vandenabeele P, Declercq W, Beyaert R, Fiers W (1995) Two tumour necrosis factor receptors: Structure and function. Trends Cell Biol 5:392-399. doi: 10.1016/S0962-8924(00)89088-1
25. Grell M, Douni E, Wajant H et al (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802. doi: 10.1016/ 0092-8674(95)90192-2
26. Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 95:570-575. doi: 10.1073/pnas.95.2.570
27. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL (1995) Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 92:1487-1493
28. Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411-452. doi: 10.1146/annurev.iy.10.040192.002211
29. Beutler B, Cerami A (1988) Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Annu Rev Biochem 57:505-518. doi: 10.1146/annurev.bi.57.070188.002445
30. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104:487-501. doi: 10.1016/S0092-8674(01)00237-9
31. Loetscher H, Gentz R, Zulauf M et al (1991) Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J Biol Chem 266:18324-18329
32. Wajant H, Henkler F, Scheurich P (2001) The TNF-receptor-associated factor family: Scaffold molecules for cytokinereceptors, kinases and their regulators. Cell Signal 13:389-400. doi: 10.1016/ S0898-6568(01)00160-7
33. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845-853. doi: 10.1016/ 0092-8674(93)90464-2
34. Hsu H, Xiong J, Goeddel DV (1995) The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 81:495-504. doi: 10.1016/0092-8674(95)90070-5
35. Stanger BZ, Leder P, Lee TH, Kim E, Seed B (1995) RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81:513-523. doi: 10.1016/0092-8674(95)90072-1
36. Duan H, Dixit VM (1997) RAIDD is a new 'death' adaptor molecule. Nature 385:86-89. doi: 10.1038/385086a0
37. Enari M, Talanian RV, Wong WW, Nagata S (1996) Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380:723-726. doi: 10.1038/380723a0
38. Vanden Berghe W, Plaisance S, Boone E et al (1998) p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 273:3285-3290. doi: 10.1074/jbc.273.6.3285
39. Chang DJ, Ringold GM, Heller RA (1992) Cell killing and induction of manganous superoxide dismutase by tumor necrosis factor-alpha is mediated by lipoxygenase metabolites of arachidonic acid. Biochem Biophys Res Commun 188:538-546. doi: 10.1016/0006-291X(92)91089-9
40. Kapadia S, Dibbs Z, Kurrelmeyer K et al (1998) The role of cytokines in the failing human heart. Cardiol Clin 16:645-656. doi: 10.1016/ S0733-8651(05)70041-2
41. Rauchhaus M, Coats AJ, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356:930-933. doi: 10.1016/S0140-6736(00)02690-8
42. Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989
43. Satoh M, Nakamura M, Tamura G et al (1997) Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 29:716-724. doi: 10.1016/ S0735-1097(96)00567-0
44. Torre-Amione G, Kapadia S, Lee J et al (1996) Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 93:704-711
45. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B (1992) The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90:693-698. doi: 10.1172/JCI115939
46. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL (1995) Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 96:1042-1052. doi: 10.1172/JCI118090
47. Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL (1997) Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 81:187-195
48. Yue P, Massie BM, Simpson PC, Long CS (1998) Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am J Physiol 275:H250-H258
49. Meldrum DR, Cleveland JC Jr, Cain BS, Meng X, Harken AH (1998) Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfusedmodel of cardiac ischemia-reperfusion injury. Ann Thorac Surg 65:439-443. doi: 10.1016/S0003-4975(97)01297-6
50. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27:1201-1206. doi: 10.1016/0735-1097(95)00589-7
51. Rauchhaus M, Doehner W, Francis DP et al (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060-3067
52. Ferrari R (1998) Tumor necrosis factor in CHF: A double facet cytokine. Cardiovasc Res 37:554-559. doi: 10.1016/S0008-6363(97)00309-X
53. MacGowan GA, Mann DL, Kormos RL, Feldman AM, Murali S (1997) Circulating interleukin-6 in severe heart failure. Am J Cardiol 79:1128-1131. doi: 10.1016/S0002-9149(96)00063-X
54. Testa M, Yeh M, Lee P et al (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28:964-971. doi: 10.1016/S0735-1097(96)00268-9
55. Torre-Amione G, Stetson SJ, Youker KA et al (1999) Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: A potential mechanism for cardiac recovery. Circulation 100:1189-1193
56. Heard SO, Perkins MW, Fink MP (1992) Tumor necrosis factor-alpha causes myocardial depression in guinea pigs. Crit Care Med 20:523-527. doi: 10.1097/00003246-199204000-00015
57. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS (1992) Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest 90:389-398. doi: 10.1172/JCI115873
58. Eichenholz PW, Eichacker PQ, Hoffman WD et al (1992) Tumor necrosis factor challenges in canines: Patterns of cardiovascular dysfunction. Am J Physiol 263:H668-H675
59. Eichacker PQ, Hoffman WD, Farese A et al (1991) TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis. J Appl Physiol 71:1979-1989
60. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387-389. doi: 10.1126/science.1631560
61. Murray DR, Freeman GL (1996) Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res 78:154-160
62. Bozkurt B, Kribbs SB, Clubb FJ Jr et al (1998) Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97:1382-1391
63. Kubota T, McTiernan CF, Frye CS et al (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627-635
64. Nakamura K, Fushimi K, Kouchi H et al (1998) Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98:794-799
65. Suematsu N, Tsutsui H, Wen J et al (2003) Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 107:1418-1423. doi: 10.1161/ 01.CIR.0000055318.09997.1F
66. Bianchi P, Kunduzova O, Masini E et al (2005) Oxidative stress by monoamine oxidase mediates receptor-independent cardiomyocyte apoptosis by serotonin and postischemic myocardial injury. Circulation 22:3297-3305. doi: 10.1161/CIRCULATIONAHA.104.528133
67. Chaiswing L, Cole MP, St Clair DK, Ittarat W, Szweda LI, Oberley TD (2004) Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol Pathol 32:536-547. doi: 10.1080/ 01926230490502601
68. Vlessis AA, Muller P, Bartos D, Trunkey D (1991) Mechanism of peroxide-induced cellular injury in cultured adult cardiac myocytes. FASEB J 5:2600-2605
69. Li YY, Feng YQ, Kadokami T et al (2000) Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 97:12746-12751. doi: 10.1073/pnas.97.23.12746
70. Shen J, O'Brein D, Yi X (2006) Matrix metalloproteinases-2 contributes to tumor necrosis factor alpha induced apoptosis in cultured rat cardiac myocytes. Biochem Biophys Res Commun 347:1011-1120. doi: 10.1016/ j.bbrc.2006.07.002
71. Krown KA, Page MT, Nguyen C et al (1996) Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 15:2854-2865. doi: 10.1172/JCI119114
72. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT (1995) Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 27:1281-1292. doi: 10.1016/ S0022-2828(05)82390-9
73. Natanson C, Eichenholz PW, Danner RL et al (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169:823-832. doi: 10.1084/jem.169.3.823
74. Castagnoli C, Stella M, Berthod C, Magliacani G, Richiardi PM (1993) TNF production and hypertrophic scarring. Cell Immunol 147:51-563. doi: 10.1006/cimm.1993.1047
75. Rawdanowicz TJ, Hampton AL, Nagase H, Woolley DE, Salamonsen LA (1994) Matrix metalloproteinase production by cultured human endometrial stromal cells: Identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. J Clin Endocrinol Metab 79:530-536. doi: 10.1210/jc.79.2.530
76. Gottschall PE, Yu X (1995) Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 64:1513-1520
77. Mann DL, McMurray JJ, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594-1602. doi: 10.1161/01.CIR.0000124490.27666.B2
78. Bozkurt B, Torre-Amione G, Warren MS et al (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:1044-1047
79. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P (1998) Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 351:1091-1093. doi: 10.1016/S0140-6736(97)09338-0
80. Mohler KM, Sleath PR, Fitzner JN et al (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370:218-220. doi: 10.1038/370218a0
81. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675-1680. doi: 10.1084/jem.177.6.1675
82. Parrillo JE, Cunnion RE, Epstein SE et al (1989) A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321:1061-1068
83. Berthonneche C, Sulpice T, Boucher F et al (2004) New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol 287:H340-H350. doi: 10.1152/ajpheart.01210.2003
84. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol (Baltimore, Md.: 1950) 147:3815-3822
85. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW et al (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol (Baltimore, Md.: 1950) 146:3444-3451
86. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765. doi: 10.1146/annurev.immunol.19.1.683
87. Wang P, Wu P, Siegel MI, Egan RW, Billah MM (1995) Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270:9558-9563. doi: 10.1074/jbc.270.16.9558
88. Levens JM, Gordon J, Gregory CD (2000) Micro-environmental factors in the survival of human B-lymphoma cells. Cell Death Differ 7:59-69. doi: 10.1038/sj.cdd.4400636
89. Moore KW, Vieira P, Fiorentino DF et al (1990) Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 248:1230-1234. doi: 10.1126/science.2161559
90. Howard M, O'Garra A (1992) Biological properties of interleukin 10. Immunol Today 13:198-200. doi: 10.1016/0167-5699(92)90153-X
91. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H (2002) The interleukin-10 family of cytokines. Trends Immunol 23:89-96. doi: 10.1016/S1471-4906(01)02149-4
92. Platzer C, Volk HD, Platzer M (1994) 5′ noncoding sequence of human IL-10 gene obtained by oligo-cassete PCR walking. DNA Seq 4:399-401. doi: 10.3109/10425179409010188
93. Platzer C, Docke WD, Volk HD, Prosch S (2000) Catecholamines trigger IL-10 release in acute systemic stress reaction by direct stimulation of its promoter/enhancer activity in monocytic cells. J Neuroimmunol 105:31-38. doi: 10.1016/S0165-5728(00)00205-8
94. Barsig J, Kusters S, Vogt K, Volk HD, Tiegs G, Wendel A (1995) Lipopolysaccharide-induced IL-10 in mice: Role of endogenous TNF-alpha. Eur J Immunol 25:2888-2893. doi: 10.1002/eji.1830251027
95. Meisel C, Vogt K, Platzer C, Randow F, Liebenthal C, Volk HD (1996) Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. Eur J Immunol 26:1580-1586. doi: 10.1002/ eji.1830260726
96. Ma W, Lim W, Gee K et al (2001) The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 276:13664-13674
97. Walter MR (2002) Strucure of interleukin-10/interleukin-10R1 complex: A paradigm for class 2 cytokine activation. Immunol Res 26:303-308. doi: 10.1385/IR:26:1-3:303
98. Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA (1995) Regulatory effects of intrinsic IL-10 in IgG immune complex-induced lung injury. J Immunol (Baltimore, Md.: 1950) 154:3454-3460
99. Furukawa Y, Becker G, Stinn JL, Shimizu K, Libby P, Mitchell RN (1999) Interleukin-10 (IL-10) augments allograft arterial disease: Paradoxical effects of IL-10 in vivo. Am J Pathol 155:1929-1939
100. vander Poll T, Marchant A, Buurman WA et al (1995) Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 155:5397-5401
101. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL (1995) Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol (Baltimore, Md.: 1950) 155:2222-2229
102. Lang R, Rutschman RL, Greaves DR, Murray PJ (2002) Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol (Baltimore, Md.: 1950) 168:3402-3411
103. Hess PJ, Seeger JM, Huber TS et al (1997) Exogenously administered interleukin-10 decreases pulmonary neutrophil infiltration in a tumor necrosis factor-dependent murine model of acute visceral ischemia. J Vasc Surg 26:113-118. doi: 10.1016/S0741-5214(97)70154-X
104. Engles RE, Huber TS, Zander DS et al (1997) Exogenous human recombinant interleukin-10 attenuates hindlimb ischemia-reperfusion injury. J Surg Res 69:425-428. doi: 10.1006/jsre.1997.5109
105. Byrne A, Reen DJ (2002) Lipopolysaccharide induces rapid production of IL-10 by monocytes in the presence of apoptotic neutrophils. J Immunol (Baltimore, Md.: 1950) 168:1968-1977
106. Levy Y, Brouet JC (1994) Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93:424-428. doi: 10.1172/JCI116977
107. Finbloom DS, Winestock KD (1995) IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol (Baltimore, Md.: 1950) 155:1079-1090
108. Clarke CJ, Hales A, Hunt A, Foxwell BM (1998) IL-10-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur J Immunol 28:1719-1726. doi:10.1002/ (SICI)1521-4141(199805)28:05<1719::AID-IMMU1719>3.0.CO;2-Q
109. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr (1999) Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868-31874. doi: 10.1074/ jbc.274.45.31868
110. Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ (2004) Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: A role for p50. Clin Exp Immunol 135:64-73. doi: 10.1111/ j.1365-2249.2004.02342.x
111. Cassatella MA, Gasperini S, Bovolenta C et al (1999) Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: Evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94:2880-2889
112. Ito S, Ansari P, Sakatsume M et al (1999) Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93:1456-1463
113. Donnelly RP, Dickensheets H, Finbloom DS (1999) The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19:563-573. doi: 10.1089/107999099313695
114. Berlato C, Cassatella MA, Kinjyo I, Gatto L, Yoshimura A, Bazzoni F (2002) Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol (Baltimore, Md.: 1950) 168:6404-6411
115. Lee TS, Chau LY (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8:240-246. doi: 10.1038/ nm0302-240
116. Pezzilli R, Billi P, Miniero R, Dig BB (1997) Serum interleukin-10 in human acute pancreatitis. Dis Sci 42:1469-1472. doi: 10.1023/ A:1018814710291
117. Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555. doi: 10.1084/jem.174.6.1549
118. Kwon OJ (1997) The role of nitric oxide in the immune response of tuberculosis Korean. Med Sci 12:481-487
119. Gougerot-Podicalo MA, Elbim C, Chollet-Martin S (1996) Modulation by pro- and anti-inflammatory cytokines of the oxidative burst of human neutrophils. Pathol Biol (Paris) 44:36-41
120. Dandona P, Mohanty P, Hamouda W, Aljada A, Kumbkarni Y, Garg R (1999) Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: A pharmacodynamic study. Clin Pharmacol Ther 66:58-65. doi: 10.1016/S0009-9236(99)70054-8
121. Mulligan MS, Jones ML, Vaporciyan AA, Howard MC, Ward PA (1993) Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol (Baltimore, Md.: 1950) 151:5666-5674
122. Shanley TP, Schmal H, Friedl HP, Jones ML, Ward PA (1995) Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (Baltimore, Md.: 1950) 154:4793-4802
123. Gunnett CA, Heistad DD, Berg DJ, Faraci FM (2000) IL-10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am J Physiol Heart Circ Physiol 279:H1555-H1562
124. Keel M, Ungethum U, Steckholzer E et al (1997) Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 90:3356-3363
125. Adamopoulos S, Parissis JT, Paraskevaidis I et al (2003) Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. Eur Heart J 24:2186-2196. doi: 10.1016/ S0195-668X(03)00480-9
126. El Azab SR, Rosseel PM, de Lange JJ et al (2002) Dexamethasone decreases the pro- to anti inflammatory cytokine ratio during cardiac surgery. Br J Anaesth 88:496-501. doi: 10.1093/bja/88.4.496
127. Giomarelli P, Scolletta S, Borrelli E, Biagioli B (2003) Myocardial and lung injury after cardiopulmonary bypass: Role of interleukin (IL)-10. Ann Thorac Surg 76:117-123. doi: 10.1016/S0003-4975(03)00194-2
128. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM (1995) IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 96:2304-2310. doi: 10.1172/ JCI118286
129. Ksontini R, MacKay SL, Moldawer LL (1998) Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. Arch Surg 133:558-567. doi: 10.1001/archsurg.133.5.558
130. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S (1994) Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 179:1695-1699. doi: 10.1084/ jem.179.5.1695
131. Kasama T, Strieter RM, Lukacs NW, Lincoln PM, Burdick MD, Kunkel SL (1995) Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 95:2868-2876. doi: 10.1172/JCI117993
132. Wang P, Wu P, Anthes JC, Siegel MI, Egan RW, Billah MM (1994) Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 83:2678-2683
133. Howard M, Muchamuel T, Andrade S, Menon S (1993) Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205-1208. doi: 10.1084/ jem.177.4.1205
134. Gerard C, Bruyns C, Marchant A et al (1993) Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177:547-550. doi: 10.1084/jem.177.2.547
135. Fearon DT, Locksley RM (1996) The instructive role of innate immunity in the acquired immune response. Science 272:50-53. doi: 10.1126/ science.272.5258.50
136. Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138-146. doi: 10.1016/0167-5699(96)80606-2
137. Stumpf C, Lehner C, Yilmaz A, Daniel WG, Garlichs CD (2003) Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci 105:45-50. doi: 10.1042/CS20020359
138. Waehre T, Halvorsen B, Damas JK et al (2002) Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 32:803-810. doi: 10.1046/ j.1365-2362.2002.01069.x
139. Lentsch AB, Shanley TP, Sarma V, Ward PA (1997) In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 15:2443-2448. doi: 10.1172/JCI119786
140. Shan K, Kurrelmeyer K, Seta Y et al (1997) The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 12:218-223. doi: 10.1097/00001573-199705000-00002
141. Meldrum DR (1998) Tumor necrosis factor in the heart. Am J Physiol 274:R577-R595
142. Mann DL (1996) The effect of tumor necrosis factor-alpha on cardiac structure and function: A tale of two cytokines. J Card Fail 2:S165-S172. doi: 10.1016/S1071-9164(96)80073-X
143. Kelly A, Lynch E, Vereker Y et al (2001) The anti-inflammatory cytokine, interleukin (IL)-10, blocks the inhibitory effect of IL-1 beta on long term potentiation. A role for JNK. J Biol Chem 276:45564-45572. doi: 10.1074/jbc.M108757200